Chat with Filing

Ask questions about this document

Please log in or register to use the chat feature. Please register first.

ER - Vivoryon Therapeutics N.V. to Report Q1 2025 Financial Results and Operational Progress on June 17, 2025

Company: Vivoryon Therapeutics N.V. Date: 2025-06-11 Language: English Register to download

Loading document preview...

Document Preview Not Available

The file type (.pdf) cannot be displayed directly here.

Open Original File

Error loading document preview. Please try the 'Open Original File' link.

You're One Click Away From The Full Filing

Instantly access this document—and 2.8M more—for free. Select your preferred method:

Continue with Google Continue with Microsoft Continue with Facebook Continue with Amazon

![](_page_0_Picture_0.jpeg)

## **Vivoryon Therapeutics N.V. to Report Q1 2025 Financial Results and Operational Progress on June 17, 2025**

**Halle (Saale) / Munich, Germany, June 11, 2025** - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (**Vivoryon**), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that it will publish its first quarter financial results for the period ended March 31, 2025 and provide a corporate update on Tuesday, June 17, 2025. The Company will host a conference call and webcast open to the public.

**Conference call details** Date: June 17, 2025 Time: 3:00 pm CEST / 9:00 am EDT

The conference call will be available via phone and webcast. The live audio webcast of the call will be available on Vivoryon´s website at: <https://www.vivoryon.com/news-and-events/presentations-webcasts/>

To join the conference call via phone, participants may pre-register and will receive dedicated dial-in details to easily and quickly access the call via the following website: <https://register-conf.media-server.com/register/BI2bf13b52bb70430396e12c44801813ac>

It is suggested participants dial into the conference call 15 minutes prior to the scheduled start time to avoid any delays in attendance.

###

## **About Vivoryon Therapeutics N.V.**

Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by its passion for ground-breaking science and innovation, the Company strives to improve patient outcomes by changing the course of severe diseases through modulating the activity and stability of pathologically relevant proteins. Vivoryon's most advanced program, varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is being evaluated to treat diabetic kidney disease. [www.vivoryon.com](https://www.globenewswire.com/Tracker?data=8PVJy9xAHUNHGuckoxKznxD1QwN6D67_nmtX8C1uy2y261V_zcnmWytheH0HBueOV3p7Y1J3cN5I0A_D1H1v1yzQQNwDcyE1NDCriCzEiEo=)

## *Vivoryon Forward Looking Statements*

*This press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of Vivoryon Therapeutics N.V. (the "Company"), estimates and projections with respect to the market for the Company's products and forecasts and statements as to when the Company's products may be available. Words such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may,"* 

![](_page_1_Picture_0.jpeg)

*"plan," "project," "predict," "should" and "will" and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management's current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. The Company's results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company's future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law.*

## **For more information, please contact:**

Investor Contacts **Vivoryon Therapeutics N.V.** Dr. Manuela Bader, Director IR & Communication Email: [IR@vivoryon.com](https://www.globenewswire.com/Tracker?data=b9UrN-wPmMEgTsB_ta3w0Tny2Xh8EmMfmrCJD5qciAb3pgarsfpEcDaFUwYP9TPGq4QcoTos5gr-rHMRevqB9Q==)

**LifeSci Advisors** Sandya von der Weid Tel: +41 78 680 05 38 Email: [svonderweid@lifesciadvisors.com](mailto:svonderweid@lifesciadvisors.com)

Media Contact **Trophic Communications** Valeria Fisher or Verena Schossmann Tel: +49 175 8041816 / +49 151 219 412 77 Email: [vivoryon@trophic.eu](https://www.globenewswire.com/Tracker?data=_Nr96kqcWfiI71wDLq6f81c9YSvG_tTKkScIbTRQySu1iUGW9PSPvmKB7xSvUQwisnBKsRYmsm5V1MQ_rhJz_yECvOrBc2WFYMKGaVNeK0Q=)